# Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

> **NCT02410200** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 22 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02410200
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-30
- **Primary completion:** 2016-09-23
- **Final completion:** 2016-09-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410200, "Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02410200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*